Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Hypomethylating agents (HMAs) in combination with venetoclax have been widely adopted as the standard of care for patients who cannot tolerate induction chemotherapy and for patients who have relapsed/refractory (R/R) acute myeloid leukemia (AML). This study retrospectively analyzed the outcomes of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Hemasphere
Hlavní autoři: Feld, Jonathan, Tremblay, Douglas, Dougherty, Mikaela, Czaplinska, Tina, Sanchez, Gillian, Brady, Claudia, Kremyanskaya, Marina, Bar-Natan, Michal, Keyzner, Alla, Marcellino, Bridget K., Gabrilove, Janice, Navada, Shyamala C., Silverman, Lewis R., El Jamal, Siraj M., Mascarenhas, John, Shih, Alan H.
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7951133/
https://ncbi.nlm.nih.gov/pubmed/33718803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000549
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky